Jazz Pharmaceuticals Aktie [WKN DE: A1JS1K / ISIN: IE00B4Q5ZN47]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Jazz Pharmaceuticals PLC

08.05.18		Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results (PR Newswire)
25.04.18		QMC announces closing of R$ 150 million facility for Brazil tower operations with ING (PR Newswire)
24.04.18		Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018 (PR Newswire)
24.04.18		Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018 (PR Newswire)
06.03.18		Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (PR Newswire)
06.03.18		Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March (PR Newswire)
02.03.18		Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea (PR Newswire)
02.03.18		Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea (PR Newswire)
27.02.18		Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results (PR Newswire)
27.02.18		Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results (PR Newswire)
23.02.18		Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease (PR Newswire)
23.02.18		Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease (PR Newswire)
13.02.18		Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018 (PR Newswire)
13.02.18		Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018 (PR Newswire)
08.02.18		National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology (PR Newswire)
08.02.18		National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology (PR Newswire)
21.12.17		Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea (PR Newswire)
21.12.17		Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea (PR Newswire)
07.12.17		Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference (PR Newswire)
07.12.17		Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference (PR Newswire)
04.12.17		Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer (PR Newswire)
04.12.17		Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer (PR Newswire)
29.11.17		Ericsson : First 5G Life Campus to Open in Belgium (PR Newswire)
28.11.17		RealNetworks Announces Kontxt, a Next Generation Mobile Messaging Platform (PR Newswire)
28.11.17		RealNetworks Announces Kontxt, a Next Generation Mobile Messaging Platform (PR Newswire)
09.11.17		Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences (PR Newswire)
09.11.17		Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences (PR Newswire)
07.11.17		Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results (PR Newswire)
07.11.17		Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results (PR Newswire)
06.11.17		FDA Ruling On DVAX This Week, XNCR On Watch, It's Impressive But Early For AVXL (RTTNews)
03.11.17		Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia (PR Newswire)
03.11.17		Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia (PR Newswire)
01.11.17		Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting (PR Newswire)
01.11.17		Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting (PR Newswire)
24.10.17		Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017 (PR Newswire)
24.10.17		Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017 (PR Newswire)
12.09.17		Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 (PR Newswire)
12.09.17		Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 (PR Newswire)
07.09.17		New Drugs Approved In August (RTTNews)
01.09.17		Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
01.09.17		Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
30.08.17		Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference (PR Newswire)
29.08.17		Biotech Stocks Facing FDA Decision In September (RTTNews)
29.08.17		Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products (PR Newswire)
29.08.17		Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products (PR Newswire)
25.08.17		Apttus Releases Intelligent Incentive Compensation Management Solution (PR Newswire)
18.08.17		Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
18.08.17		Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
17.08.17		Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 (PR Newswire)
17.08.17		Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 (PR Newswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Jazz Pharmaceuticals Peer Group Nachrichten

31.05.16

Jazz Pharmaceuticals übernimmt Celator für 1,5 Milliarden

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

Nach NVIDIA & Co: Diese beiden Unternehmen könnten den nächsten Aktiensplit erleben

Bitcoin, Ether & Co. in der vergangenen Woche: Wochenbilanz der Kryptowährungen in KW 2

APA - N A C H R I C H T E N Ü B E R B L I C K

Steinmeier setzt Neuwahlen für 23. Februar an

Konkurrenz für D-Wave Quantum: Auf diese Geschäftseinheit von Honeywell hält ein Analyst große Stücke

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 01:03
Kaufwert:	EUR
	Hinzufügen Speichern